Panel 1
Tirone David valve-sparing aortic root replacement and cusp repair for bicuspid aortic valve disease

https://doi.org/10.1016/j.jtcvs.2012.11.043Get rights and content
Under an Elsevier user license
open archive

Objectives

The durability of valve-sparing aortic root replacement with or without cusp repair in patients with bicuspid aortic valve (BAV) disease is questioned. We analyzed the results of 75 patients with a BAV undergoing Tirone David reimplantation valve-sparing aortic root replacement.

Methods

Average age was 45 ± 10 years; 80% were male; 31% had 2+ or greater aortic regurgitation (AR); annular diameter averaged 28 ± 3 mm; 32% had a Sievers' type 0 BAV, and 66% underwent concomitant cusp repair (usually cusp free margin shortening) to correct prolapse. Early (6 ± 3 days) and late (2.9 ± 1.7, 1-10 years) postoperative echocardiographic results were compared (cumulative echocardiographic follow-up, 190 patient-years; median late interval, 2 years [interquartile range, 0.68, 4.2]). Seven patients remained at risk beyond 6 years. Clinical outcome and valve function were analyzed using log–rank calculations.

Results

Actuarial survival was 99% ± 2%; freedom from reoperation was 90% ± 5%, infection 98% ± 2%, and stroke 100% at 6 years. After initial improvement in degree of AR (P < .001), minor subclinical progression of AR was observed (P > .5); however, freedom from AR of more than 2+ was 100%. Cusp free margin shortening was not associated with valve deterioration, but commissural suspensory polytetrafluoroethylene neochord creation (n = 4) portended a higher probability of recurrent AR (P = .025).

Conclusions

After David procedure and cusp repair in patients with a BAV, midterm clinical and valve function outcomes were favorable out to 6 years. More follow-up is required to determine long-term valve durability and the hazard of other clinically important late adverse events, including eventual reoperation, to beyond 10 years.

Abbreviations and Acronyms

AR
aortic regurgitation
BAV
bicuspid aortic valve
CPB
cardiopulmonary bypass
CR
cusp repair
PTFE
polytetrafluoroethylene
IQR
interquartile range
TEE
transesophageal echocardiography
TTE
transthoracic echocardiogram
V-SARR
valve-sparing aortic root replacement
VS-MOD
V–Stanford modification
Vmax
maximal velocity

CTSNet classification

20.1
26.1
35.1

Cited by (0)

F.A.K. is currently at the Department of Cardiovascular Surgery, Heart Center Freiburg University, Germany.

J.-P.E.K. is currently at Linköping University Hospital, Department of Cardiothoracic Surgery, Linköping, Sweden.

This work was supported by the U.S.-Norway Fulbright Foundation, the Swedish Heart-Lung Foundation and the Swedish Society for Medical Research (Dr Kvitting).

Disclosures: Dr Mitchell reports consulting fees from W.L. Gore. Dr Fischbein reports consulting fees from Edwards and grant support from the National Marfan Society. Dr Miller reports the following: Consultant to GenTAC/NHLBI under contract to RTI; Consultant to Abbot Vascular Mitraclup; Consultant to Medtronic Cardio Vascular Division Inc; Consultant to PARTNER US Trial—Percutaneous AVR; Consultant to Medtronic Heart Valve Division; PI for NIH Research Grant; Research Grant from the PARTNER Trial: Placement of Aortic Transcatheter Valve Trial, Edwards LifeSciences. Drs Kari, Liang, Escobar Kvitting, and Stephens have nothing to disclose with regard to commercial support.

Read at the American Association for Thoracic Surgery Aortic Symposium, New York, New York, April 26-27, 2012.